Celularity Inc
Celularity Inc. (Nasdaq: CELU) is a cellular and regenerative medicine company developing therapies and biomaterial products derived from postpartum human placentas. Its pipeline includes off-the-shelf, donor-derived natural killer cells and mesenchymal-like adherent stem cells for age-related degenerative, immune,… From the company’s description.
Over the twelve months to Jun 30, 2026, Celularity Inc reported revenue of $18.67M, down 58.1% from a year earlier, and a net loss of $45.86M. Its operating margin was −264.3%, and operations used $8.92M in cash. In fiscal 2025, it reported revenue of $26.55M, down 51.0% from fiscal 2024, and a net loss of $91.72M.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Celularity Inc does
In the company’s own words
Celularity Inc. (Nasdaq: CELU) is a cellular and regenerative medicine company developing therapies and biomaterial products derived from postpartum human placentas. Its pipeline includes off-the-shelf, donor-derived natural killer cells and mesenchymal-like adherent stem cells for age-related degenerative, immune, infectious and cancer-related conditions. The company also markets placental tissue products for wound care, soft-tissue repair and reconstructive procedures, including Biovance, Biovance 3L, Interfyl, CentaFlex and Rebound. Its biobanking business collects, processes and stores cord blood and placenta-derived cells and tissue for expectant parents, while its manufacturing capabilities support contract development and production services for third parties. Celularity reports commercial biomaterial sales in its Degenerative Disease operating segment; the business also includes cellular therapy development and biobanking activities. The company operates a 147,215-square-foot facility for manufacturing, research and biobanking. Its website is not stated in the provided filing text.
Company details
- Sector
- Health Care
- Industry (SIC)
- Pharmaceutical Preparations
- Headquarters
- FLORHAM PARK, NJ
- Fiscal year end
- December
- CIK
- 1752828
- SIC
- 2834
Financial performance, year by year
Fiscal 2019–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Celularity Inc — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Celularity Inc’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Could not be determined for this company: bond issues.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Celularity Inc and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Celularity Inc's earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Celularity Inc's last four quarterly filings that the numbers alone won't show?”